-+ 0.00%
-+ 0.00%
-+ 0.00%

INVENTISBIO CO LTD: AT WEEK 16, BOTH NOMELCITINIB TREATMENT GROUPS ACHIEVED PASI 90 IN OVER 70% OF PATIENTS

Reuters·11/02/2026 11:00:09

Please log in to view news